Literature DB >> 29858434

Clostridium difficile infection and antibiotic-associated diarrhoea.

Benjamin H Mullish1, Horace Rt Williams2.   

Abstract

Antibiotic-associated diarrhoea is among the most common adverse events related to antibiotic use. Most cases are mild, but Clostridium difficile infection causes a spectrum of disease, ranging from occasional diarrhoea to colitis, toxic megacolon, and potentially death. Recent developments in our understanding of the biology of the gut microbiota have provided new insights into the pathogenesis of these conditions, and have revealed a role for manipulation of the gut microbiota as a novel therapeutic approach. This review will give an overview of the assessment of these conditions, before focusing on the rapidly developing area of their treatment. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; antibiotics; diarrhoea; faecal microbiota transplant; microbiota

Mesh:

Substances:

Year:  2018        PMID: 29858434      PMCID: PMC6334067          DOI: 10.7861/clinmedicine.18-3-237

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  19 in total

Review 1.  Adverse events in faecal microbiota transplant: a review of the literature.

Authors:  M Baxter; A Colville
Journal:  J Hosp Infect       Date:  2015-12-15       Impact factor: 3.926

2.  Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.

Authors:  G Cammarota; L Masucci; G Ianiro; S Bibbò; G Dinoi; G Costamagna; M Sanguinetti; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2015-03-01       Impact factor: 8.171

3.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

Review 4.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

5.  An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings.

Authors:  Mamoon A Aldeyab; Mary P Kearney; Michael G Scott; Motasem A Aldiab; Yaser M Alahmadi; Feras W Darwish Elhajji; Fidelma A Magee; James C McElnay
Journal:  J Antimicrob Chemother       Date:  2012-08-16       Impact factor: 5.790

Review 6.  Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection.

Authors:  B H Mullish; J R Marchesi; M R Thursz; H R T Williams
Journal:  QJM       Date:  2014-09-04

7.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Authors:  Mark H Wilcox; Dale N Gerding; Ian R Poxton; Ciaran Kelly; Richard Nathan; Thomas Birch; Oliver A Cornely; Galia Rahav; Emilio Bouza; Christine Lee; Grant Jenkin; Werner Jensen; You-Sun Kim; Junichi Yoshida; Lori Gabryelski; Alison Pedley; Karen Eves; Robert Tipping; Dalya Guris; Nicholas Kartsonis; Mary-Beth Dorr
Journal:  N Engl J Med       Date:  2017-01-26       Impact factor: 91.245

Review 8.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

9.  European consensus conference on faecal microbiota transplantation in clinical practice.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Herbert Tilg; Mirjana Rajilić-Stojanović; Patrizia Kump; Reetta Satokari; Harry Sokol; Perttu Arkkila; Cristina Pintus; Ailsa Hart; Jonathan Segal; Marina Aloi; Luca Masucci; Antonio Molinaro; Franco Scaldaferri; Giovanni Gasbarrini; Antonio Lopez-Sanroman; Alexander Link; Pieter de Groot; Willem M de Vos; Christoph Högenauer; Peter Malfertheiner; Eero Mattila; Tomica Milosavljević; Max Nieuwdorp; Maurizio Sanguinetti; Magnus Simren; Antonio Gasbarrini
Journal:  Gut       Date:  2017-01-13       Impact factor: 23.059

Review 10.  The gut microbiota and host health: a new clinical frontier.

Authors:  Julian R Marchesi; David H Adams; Francesca Fava; Gerben D A Hermes; Gideon M Hirschfield; Georgina Hold; Mohammed Nabil Quraishi; James Kinross; Hauke Smidt; Kieran M Tuohy; Linda V Thomas; Erwin G Zoetendal; Ailsa Hart
Journal:  Gut       Date:  2015-09-02       Impact factor: 23.059

View more
  20 in total

Review 1.  The Human Microbiota and Asthma.

Authors:  Aaron Ver Heul; Joseph Planer; Andrew L Kau
Journal:  Clin Rev Allergy Immunol       Date:  2019-12       Impact factor: 8.667

Review 2.  Regulation of Clostridioides difficile toxin production.

Authors:  Aritri Majumdar; Revathi Govind
Journal:  Curr Opin Microbiol       Date:  2021-11-12       Impact factor: 7.934

3.  Low Concentration of Fecal Valeric Acid at 1 Year of Age Is Linked with Eczema and Food Allergy at 13 Years of Age: Findings from a Swedish Birth Cohort.

Authors:  Monica Gio-Batta; Karin Spetz; Malin Barman; Lennart Bråbäck; Elisabeth Norin; Bengt Björkstén; Agnes E Wold; Anna Sandin
Journal:  Int Arch Allergy Immunol       Date:  2021-11-26       Impact factor: 3.767

4.  Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection.

Authors:  Zainab I Abdali; Tracy E Roberts; Pelham Barton; Peter M Hawkey
Journal:  EClinicalMedicine       Date:  2020-06-27

5.  Design and Expression of Specific Hybrid Lantibiotics Active Against Pathogenic Clostridium spp.

Authors:  Rubén Cebrián; Alicia Macia-Valero; Afif P Jati; Oscar P Kuipers
Journal:  Front Microbiol       Date:  2019-09-24       Impact factor: 5.640

Review 6.  Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI.

Authors:  I Castro; M Tasias; E Calabuig; M Salavert
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553

7.  Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.

Authors:  Michelle Ghert; Patricia Schneider; Gordon Guyatt; Lehana Thabane; Roberto Vélez; Timothy O'Shea; R Lor Randall; Robert Turcotte; David Wilson; Jay S Wunder; André Mathias Baptista; Edward Y Cheng; Yee-Cheen Doung; Peter C Ferguson; Victoria Giglio; James Hayden; Diane Heels-Ansdell; Shah Alam Khan; Venkatesan Sampath Kumar; Paula McKay; Benjamin Miller; Michiel van de Sande; Juan P Zumárraga; Mohit Bhandari
Journal:  JAMA Oncol       Date:  2022-03-01       Impact factor: 33.006

8.  Clostridium difficile infection in an academic medical center in Saudi Arabia: prevalence and risk factors.

Authors:  Mai Alalawi; Seba Aljahdali; Bashaer Alharbi; Lana Fagih; Raghad Fatani; Ohoud Aljuhani
Journal:  Ann Saudi Med       Date:  2020-08-06       Impact factor: 1.526

9.  In Vitro Bactericidal Effects of Photodynamic Therapy Combined with Four Tetracyclines against Clostridioides difficile KCTC5009 in Planktonic Cultures.

Authors:  Sung Sook Choi; Hui Yeong Oh; Eui Jin Kim; Hae Kyung Lee; Hyung Keun Kim; Hyun Ho Choi; Sang Woo Kim; Hiun Suk Chae
Journal:  Pathogens       Date:  2020-04-11

10.  Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid.

Authors:  Frederick Wittke; Catherine Vincent; James Chen; Barry Heller; Heidi Kabler; J Scott Overcash; François Leylavergne; Guennaëlle Dieppois
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.